Back to Single Peptide Protocols
Single PeptideGrowth Hormone & Performance5 mg vialOnce weeklySubcutaneousGHRH
CJC-1295 DAC (5 mg Vial) Dosage Protocol
CJC-1295 DAC dosage protocol for the 5 mg vial. Long-acting GHRH analogue with once-weekly dosing.
Vial Size
5 mg
Route
Subcutaneous
Frequency
Once weekly
Dose Range
1.0–2.0 mg/week
Dosage Schedule
| Period | Dose |
|---|---|
| Weeks 1–2 (starter) | 1.0 mg |
| Weeks 3+ (maintenance) | 1.0–2.0 mg |
Route: Subcutaneous · Frequency: Once weekly · Cycle: 8–12 weeks
How It Works
CJC-1295 DAC (Drug Affinity Complex) has a half-life of 6–8 days due to its albumin-binding DAC moiety, enabling once-weekly dosing with sustained GH elevation.
Potential Benefits
- •Sustained GH elevation with once-weekly dosing.
- •Supports lean body composition and recovery.
- •Convenient dosing schedule.
Side Effects & Risks
- •Water retention more pronounced than No-DAC version.
- •Possible GH bleed (sustained rather than pulsatile release).
Important Notes
- DAC version produces sustained GH elevation, not pulsatile release.
- Some researchers prefer No-DAC for more physiological GH pulsatility.
Storage Instructions
- Lyophilized: −20 °C (−4 °F).
- Once mixed: 2–8 °C; use within 14–21 days.
References
- [1]Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab 2006.View Source
Research & Educational Use Only: This protocol is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions related to peptides or any other compounds.